fashion -WSS

fashion

author：knowledge 2025-09-27 22:48:38 - browse：1

Christine Kao/STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves. So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers.

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products. CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： In utero gene editing: an explainer

WSS

Community Health Systems hospitals under DOJ investigation

To avoid data mishandling cases, universities eye AI and other tools

Robert F. Kennedy is pitching centrism on health, even on abortion

A new nitrogen execution bill also undermines medical licensing

The dental labor crisis is a moment of opportunity

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

explore

fashion

leisure time

Supreme Court strikes down use of affirmative action

Robert F. Kennedy is pitching centrism on health, even on abortion

Jerome Adams on the need for new antivirals for Covid

Antivenom research: Lessons from HIV applied in search for universal antidote

Medical records are filled with copy

Readout LOUD podcast: How biotech is using artificial intelligence

Hepatitis C has a cure — but many Americans still lack access to it

What should King Charles tell the public about his cancer?

BioMarin wins approval for gene therapy to treat hemophilia A

Doctors' information doesn't help them choose wisely when sick

knowledge

The Harvard botanist who searched for psychedelics in the Amazon

Dario to buy mental health app maker Twill in cash and stock deal

Industry veterans launch new biotech VC with $310M

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Biden report: The neurospychology of memory and aging

knowledge

hotspot

focus

focus